secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001193805-23-000611
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic appoints MS expert Dr. Richard Rudick to Board; Dr. Ossipow to retire at 2023 meeting
--------------------------------------------------------------------------------

- Dr. Rudick appointed as Class III director effective April 26, 2023; term ends at 2023 Annual Meeting.
- Received option to purchase 32,000 shares, vesting monthly over three years, exercise price at grant date closing price.
- Dr. Vincent Ossipow will not stand for re-election at 2023 Annual Meeting, continues until then; no disagreement cited.
- Board size increased from 7 to 8 directors upon Rudick's appointment.
- Rudick brings 35+ years of MS expertise from Cleveland Clinic and Biogen, expected to support vidofludimus calcium development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380523000611/0001193805-23-000611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380523000611/e618552_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-000611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer